what is an announcement bar

The Gut Cancer Foundation is thrilled to announce a continued partnership with The Chiller NZ as the official alcohol-free drinks partner for Give It Up for Gut Cancer 2025. With their wide range of 0% beers, wines, and spirits, The Chiller is providing the perfect alcohol-f...
Read more
The Gut Cancer Foundation welcomes the long-awaited announcement from Pharmac that New Zealand patients with advanced or metastatic unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer, will finally gain access to publicly funded treatment with a...
Read more
Dr Howe Mao is a general surgeon specialising in hepatopancreaticobiliary (HPB) surgery. He is currently a research fellow and PhD candidate at the University of Auckland, with a focused interest in the genetics of pancreatic cancer. Late-stage diagnosis, disease recurr...
Read more
Increased sugar intake is a major contributing factor to rising obesity levels which research shows increase the risk of developing gut cancers including; oesophageal, stomach, liver and pancreatic cancer.The main cause of weight gain comes down to sugar intake, in fact, it ...
Read more
One of the options for GIVE IT UP for Gut Cancers is to go booze-free. After Christmas and New Years, many of us are thinking about our alcohol consumption and this has been a popular choice for GIU 2025! Here's some food for thought:❌ Limiting alcohol consumption can help...
Read more
Today Pharmac has confirmed that Lenvatinib (Lenvima) will be available from 1 December for eligible patients with advanced unresectable Hepatocellular Carcinoma.This is a very welcome but long-awaited step forward and the first-time liver cancer patients in Aotearoa will be...
Read more
1 November Update: Cetuximab (Erbitux) is now funded for some bowel  cancer patients. To find out more, check eligibility and download resources including questions to ask your medical team, visit the Erbitux website.GCF is delighted to see today’s announcement that C...
Read more
The Gut Cancer Foundation (GCF) has today provided feedback to Pharmac as part of their consultation process for funding the liver cancer treatment, lenvatinib (Lenvima). Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an ...
Read more
The Gut Cancer Foundation is heartened to receive news of widened access of pembrolizumab (Keytruda) for microsatellite instability high or deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) patients.  Pharmac has listened to clinici...
Read more
Earlier this month, Pharmac called for feeback on their proposal to widen access to Pembrolizumab to treat microsatellite instability-high or deficient mismatch repair (MSI-H/dMMR) colorectal cancer.We and the community we represent welcome the proposal. For a patient g...
Read more
Load more
Loading...
Load more
Loading...